Cancer Letters
Volume 284, Issue 1 , Pages 7-14 , 18 October 2009

Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: Clinical implications

Received 28 November 2008 ,Revised 2 February 2009 ,Accepted 4 February 2009.

References 

  1. Bench AJ, Cross NCP, Huntly BJP, Nacheva EP, Green AR. Myeloproliferative disorders. Best Pract. Res. Clin. Haematol. 2001;14:531–551
  2. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin. Proc. 2003;78:174–194
  3. Thiele J, Krasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann. Hematol. 2003;82:148–152
  4. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin. Hematol. 1999;36:9–13
  5. Spivak JL. Polycythemia vera: myths, mechanisms and management. Blood. 2002;100:4272–4290
  6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  7. Tefferi A. Classic and atypical myeloproliferative disorders. Best Pract. Res. Clin. Haematol. 2006;19:361–364
  8. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 2005;280:22788–22792
  9. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061
  10. Levine RL, Wadleigh M, Cools J, Ebert BJ, Werning G, Huntly BJP, et al Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397
  11. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144–1148
  12. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain of function mutation in JAK2 is frequently found in patients with myeloproliferative disorders. New Engl. J. Med. 2005;352:1779–1790
  13. Tefferi A. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J. 2007;13:366–371
  14. Tefferi A. JAK and MPL mutations in myeloid malignancies. Lukemia Lymphoma. 2008;49:388–397
  15. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br. J. Haematol. 2006;134:366–384
  16. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162–2168
  17. Sidon P, El Housni H, Dessars B, Heirmann P. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia. 2006;20:1622
  18. Rapado I, Albizua E, Ayala R, Hernandez JA, Garcia-Alonso L, Grande S, et al. Validity test study of JAK2V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann. Hematol. 2008;87:741–749
  19. Tefferi A. New insights into the pathogenesis and drug treatment of myelofibrosis. Curr. Opin. Hematol. 2006;13:87–92
  20. Dupont S, Masse A, James C, Teyssandier I, Lecluse Y, Larbet F, et al The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110:1013–1021
  21. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107:4274–4281
  22. Bumm TGP, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, et al. Characterization of murine JAKV617F positive myeloproliferative disease. Cancer Res. 2006;66:11156–11165
  23. Tefferi A, Gilliland G. Classification of chronic myeloid disorders: from Dameshec towards a semi-molecular system. Best Pract. Res. Clin. Haematol. 2006;19:365–385
  24. Chen G, Prchal JT. Polycythemia vera and molecular basis: an update. Best Pract. Res. Clin. Haematol. 2006;19:387–397
  25. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207–1209
  26. Levine RL, Loriaux M, Huntly BJP, Loh ML, Beran M, Stoffregen E, et al The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377–3379
  27. Tono C, Xu G, Toki T, Takahashi Y, Sasaki S, Terui K, et al. JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia. Leukemia. 2005;19:1843–1844
  28. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, et al. The JAK2 V617F mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005;106:2920–2921
  29. Sulong S, Case M, Minto L, Wilkins B, Hall A, Irving J. The V617F mutation in JAK2 is not found in childhood acute lymphoblastic leukemia. Br. J. Haematol. 2005;130:964–972
  30. Johan MF, Goodeve AC, Bowen DT, Frew ME, Reitly JT. JAK2 V617F mutation is uncommon in chronic myelomonocytic leukemia. Br. J. Haematol. 2005;130:968
  31. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528–1534
  32. Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, et al Prevalence of the activating JAK2 tyrosine kinase mutation in the Budd-Chiari syndrome. Gastroenterology. 2006;130:2031–2038
  33. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New Engl. J. Med. 2007;356:459–468
  34. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21:1960–1963
  35. Percy MJ, Scott LM, Erber WN, Harisson CN, Reilly JT, Jones FG, et al. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica. 2007;92:1585–1589
  36. Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda RC. Clonal heterogeneity in polycythemia vera patients with JAK2 exon 12 and JAK2V617F mutations. Blood. 2008;111:3863–3866
  37. Rothlisberger B, Huber A, Bargetzi M, Mendez A, Heizmann M. JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia Lymphoma. 2008;49:586–588
  38. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis: recombinations from an ad hoc international expert panel. Blood. 2007;110:1092–1097
  39. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22
  40. Klipivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia. 2008;22:1813–1817
  41. Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia. 2008;22:1841–1848
  42. Vannucchi AM, Antonioli E, Gugliemelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299–1307
  43. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2008;111:2785–2789
  44. Kralovics R, Teo SS, Theocharides A, Buser AS, Tichelli A, Skoda RC. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108:1377–1380
  45. Kawamata N, Ogawa S, Yamamoto G, Lehmann S, Levine RL, Pikman Y, et al. Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Exp. Hematol. 2008;36:1471–1479
  46. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. 2007;7:673–683
  47. Rumi E. Familial chronic myeloproliferative disorders: the state of the art. Hematol. Oncol. 2008;26:131–138
  48. Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, et al. JAK2V617F as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006;107:2206–2211
  49. Cario H, Goerttler PS, Steimle C, Levine RL, Pahl HL. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythemia vera. Br. J. Haematol. 2005;130:800–801
  50. Bellanne-Chantelot C, Chaumared I, Labopin M, Bellanger F, Barbu V, De Toma C, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108:346–352
  51. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M. Increased risks of polycythemia vera essential thrombocythemia and myelofibrosis among 24577 first-degree relatives of 11039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112:2199–2204
  52. Panani AD. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications. Cancer Lett. 2007;255:12–25
  53. Kralovics R, Guan V, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp. Hematol. 2002;30:229–236
  54. Schaub FX, Tiedt R, Hermouet S, Girodon F, Kralovics R, Tichelli A, et al. Characterization of del20q in peripheral blood of MPD patients using copy number analysis and high resolution oligonucleotide CGH array. Blood. 2007;110:457A–458A
  55. Schaub FX, Jager R, Looser R, Hao-Shen H, Hermouet S, Girodon F, et al. Clonal analysis of deletions on chromosome20q and JAK2V617F in MPD suggests that del20q acts independently and is not one of the pre-disposing mutations for JAK2V617F. Blood. 2008;
  56. Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonarity studies, cytogenetic associations and role in leukemic transformation. Blood. 2006;108:3548–3555
  57. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, et al. Leukemic blasts in transformed JAK2V617F-positive myeloproliferative disorders are frequently negative for the JAK2V617F mutation. Blood. 2007;110:375–379
  58. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood. 2006;108:2435–2437
  59. Ganly P, Hanrahan V, Baker B, Romeril K. Identification of JAK2 V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera. Am. J. Hematol. 2007;82:80–82
  60. Rossi D, Cortini F, Deambrogi C, Barbieri C, Cerri M, Franceschetti S, et al. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera. Leukemia Res. 2007;31:97–101
  61. Blacklock HA, Royle GA. Idiopathic erythocytosis: a declining entity. Br. J. Haematol. 2001;115:774–781
  62. Mesa RA, Powell H, Lasho TL, Dewald GW, McClure R, Tefferi A. JAK2 V617F and leukemic transformation in myelofibrosis with myeloid metaplasia. Leukemia Res. 2006;30:1457–1460
  63. Rossi D, Deambrogi C, Capello D, Cerri M, Lunghi M, Parvis G, et al. JAK2 V617F mutation in leukemic transformation of Philadelphia negative chronic myeloproliferative disorders. Br. J. Haematol. 2006;135:267–268
  64. Ma W, Kantarjian H, Verstovsek S, Jilani I, Gorre M, Giles F, et al Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. Br. J. Haematol. 2006;134:341–342
  65. Speletas M, Katodritou E, Daiou C, Mandala E, Papadakis E, Kioumi A, et al. Correlation of JAK2 V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leukemia Res. 2007;31:1053–1062
  66. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa R, Li C-Y, et al. The JAK2 V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br. J. Haematol. 2005;131:320–328
  67. Campbell PJ, Scott LM, Buck G, Wheatley K, East CI, Marsden JT, et al Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–1953
  68. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliot M, Mesa R, et al The clinical phenotype of wild-type, heterozygous and homozygous JAK2V617F in polycythemia vera. Cancer. 2006;106:631–635
  69. Vannucchi AM, Antonioli E, Gugliemelli P, Rambaldi A, Barosi G, Marchioli R, et al Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840–846
  70. Vannucchi AM, Antonioli E, Gugliemelli P, Longo G, Pancrazzi A, Ponziani V, et al. MPD Research Consortium, Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia. 2007;21:1952–1959
  71. Tefferi A, Strand LL, Lasho TL, Knudson RA, Finke CM, Gangat N, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia. 2007;21:2074–2075
  72. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors and the role of leucocytes and JAK2V617F. Semin. Thromb. Hemost. 2007;33:313–320
  73. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am. J. Hematol. 2008;83:363–365
  74. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007;109:2279–2284
  75. Wolanskyj A, Lasho TL, Schwager SM, McClure R, Wadleigh M, Lee SJ, et al. JAK2 V617F mutation in essential thrombocythemia: clinical associations and long-term prognostic relevance. Br. J. Haematol. 2005;131:208–213
  76. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, et al. Clinical implications of the JAK2V617F mutation in essential thrombocythemia. Leukemia. 2005;19:1847–1849
  77. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythemia. Br. J. Haematol. 2005;132:244–250
  78. Heller PG, Lev PR, Salim JP, Kornblihtt LI, Goette NP, Chazarreta CD, et al. JAK2 V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphprylation status. Eur. J. Haematol. 2006;77:210–216
  79. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and JAK2 mutation status. Blood. 2007;109:2310–2313
  80. Antonioli E, Gugliemelli P, Bogani C, Pancrazzi A, Longo G, Ponziani V, et al. Myeloproliferative Disorders Research Consortium (MPD-RC), Influence of JAK2 V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008;93:41–48
  81. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythemia: independence of the V617F allele burden. Hematology. 2008;13:71–76
  82. Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, Hasselbatch HC, et al V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107:2098–2100
  83. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Gugliemelli P, Antonioli E, et al JAK2V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110:4030–4036
  84. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia free survival. Leukemia. 2008;22:756–761
  85. Tefferi A. Essential thrombocythemia, polycythemia vera and myelofibrosis: current management and the prospect of targeted therapy. Am. J. Hematol. 2008;83:491–497
  86. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008;22:23–30

PII: S0304-3835(09)00088-3

doi: 10.1016/j.canlet.2009.02.010

Cancer Letters
Volume 284, Issue 1 , Pages 7-14 , 18 October 2009

Article Tools

* Image Usage & Resolution